Full profile
| Also known as | Mangifera indica leaf extract, Mangiferin |
|---|---|
| Best for | Acute alertness without stimulant activation · Attention accuracy on demanding tasks |
| Evidence grade | Grade C — Limited — early or small human trials |
| Studied dose range | 100–300 mg/day; 300 mg is the most-studied acute dose. |
| Time to effect | Acute — effects studied within 1–2 hours of a single dose. |
| Best form | Zynamite (Mangifera indica leaf extract standardized to ~60% mangiferin). |
Evidence, honestly graded
Wightman 2020 (Nutrients 12(8):2194, PMC7468873) gave 70 healthy adults a single 300 mg Zynamite dose and found improved attention accuracy and episodic memory versus placebo, without the cardiovascular activation seen with stimulants. Downgraded from B to C on 2026-07-11: this rests on one Nektium-sponsored acute trial (two manufacturer-affiliated authors) with no independent replication, and a single sponsor-funded trial does not meet the bar for B. Chronic daily use remains a separate, weaker (Emerging-level) question, not yet supported by repeated-dosing human trials.
See the full grading rubric — study type, replication, population match, and dose adequacy — in The Evidence Standard.
Side effects
- Generally well tolerated
- Limited long-term human safety data given the acute-focused trial base
Who should avoid it or check first
- Pregnant or breastfeeding without clinician guidance (limited data)
Interactions
- COMT-inhibition mechanism — caution combining with stimulant medications, MAOIs, L-DOPA, or L-tyrosine supplementation — discuss with a clinician
Stacks well with
Use caution stacking with
- L-Tyrosine at high dose (overlapping catecholamine-pathway mechanism)
What to look for on a label
- Specify the branded Zynamite extract and its mangiferin standardization — plain "mango leaf extract" doesn't guarantee the studied material.
- Position as acute/single-dose alertness support; chronic-use claims outrun the current evidence.
References
- Wightman 2020, Nutrients — Zynamite acute attention RCT. Wightman EL, Jackson PA, Forster J, Khan J, Wiebe JC, Gericke N, Kennedy DO. Nutrients 2020;12(8):2194. n=70 healthy adults; single 300 mg dose improved attention accuracy and episodic memory versus placebo, without cardiovascular activation. Sponsored by Nektium Pharma. PMC7468873. Educational, not a product claim.
Grades and studied doses are our conservative reading of the human research, shown for education. They are not product claims, and a studied dose is not a recommended dose.
Revision history
Every change to this ingredient's evidence status, dated and explained. The full cross-library log lives at Evidence Updates.
- 2026-07-11Grade changeGrade B → Grade C
Downgraded from B to C. The attention/memory result rests on a single acute-dose trial in healthy adults; a B needs independent replication that does not yet exist.
See how Zynamite compares on grade, dose, and goal in the Evidence Explorer.
